Brief: Cytomx Therapeutics Announces FDA Clearance Of Ind Applications For Cx-2051, A Probody® Antibody Drug Conjugate (Adc) Targeting Epcam And Cx-801, A Conditionally Activated Interferon Alpha-2B
24/01/2024 15:28
Jan 24 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATIONS
FOR CX-2051, A PROBODY® ANTIBODY DRUG CONJUGATE (ADC) TARGETING
EPCAM AND CX-801, A CONDITIONALLY ACTIVATED INTERFERON ALPHA-2B
* CYTOMX THERAPEUTICS INC: INITIATION OF CX-2051 PHASE 1
CLINICAL
STUDY IN EPCAM POSITIVE TUMORS INCLUDING COLORECTAL CANCER
ANTICIPATED IN 1H 2024
* CYTOMX: INITIATION OF CX-801 PHASE 1 STUDY IN SOLID TUMORS
INCLUDING MELANOMA, RENAL, & HEAD AND NECK SQUAMOUS CELL
CARCINOMA ANTICIPATED IN 1H 2024
Source text for Eikon: ID:nGNX7BB9p1
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway